首页> 外文期刊>Genetics in medicine >Diagnosis and management of glycogen storage diseases type VI and IX: a clinical practice resource of the American College of Medical Genetics and Genomics (ACMG)
【24h】

Diagnosis and management of glycogen storage diseases type VI and IX: a clinical practice resource of the American College of Medical Genetics and Genomics (ACMG)

机译:糖原储存疾病的诊断和管理类型VI和IX:美国医学遗传学学院临床实践资源(ACMG)

获取原文
获取原文并翻译 | 示例
           

摘要

Purpose: Glycogen storage disease (GSD) types VI and IX are rare diseases of variable clinical severity affecting primarily the liver. GSD VI is caused by deficient activity of hepatic glycogen phosphorylase, an enzyme encoded by the PYGL gene. GSD IX is caused by deficient activity of phosphorylase kinase (PhK), the enzyme subunits of which are encoded by various genes: alpha (PHKA1, PHKA2), beta (PHKB) gamma (PHKG1, PHKG2), and delta (CALM1, CALM2, CALM3). Glycogen storage disease types VI and IX have a wide spectrum of clinical manifestations and often cannot be distinguished from each other, or from other liver GSDs, on clinical presentation alone. Individuals with GSDs VI and IX can present with hepatomegaly with elevated serum transaminases, ketotic hypoglycemia, hyperlipidemia, and poor growth. This guideline for the management of GSDs VI and IX was developed as an educational resource for health-care providers to facilitate prompt and accurate diagnosis and appropriate management of patients.
机译:目的:糖原储存疾病(GSD)型VI和IX型是可变临床严重程度主要影响肝脏的罕见疾病。 GSD VI是由肝糖原磷酸化酶的缺乏活性引起的,该酶由PyGL基因编码。 GSD IX是由磷酸化酶激酶(PHK)的缺乏活性引起的,其酶亚基由各种基因编码:α(PHKA1,PHKA2),β(PHKB)γ(PHKG1,PHKG2)和DELTA(CALL1,CALL2,平静3)。糖原储存疾病类型VI和IX具有广泛的临床表现,并且通常不能彼此区分,或者来自其他肝脏GSD,单独临床呈现。具有GSDS VI和IX的个体可以呈现肝肿大,具有升高的血清转氨酶,酮症低血糖,高脂血症和增长差。本署署长VI和IX管理指南被制定为卫生保健提供商的教育资源,以促进促进和准确的诊断和适当管理患者。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号